Fibulink Syndesmosis Repair System With Early Full-Weight Bearing
Maimonides Medical Center · with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · NCT06085586
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 22+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 56
- US sites recruiting
- 1
- Study start
- July 13, 2023
- Record last updated
- March 20, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of the study is to evaluate the ability of the Fibulink Syndesmosis Repair System to maintain reduction of the ankle syndesmosis. Appropriate reduction of the syndesmosis is critical due the changes in tibiotalar contact pressure observed in cadaveric studies.6,7 Malreduction and instability of the distal tibiotalar joint can lead to chronic instability, increased articular damage and ultimately degenerative arthritis.7,8 Medial to lateral translation of distal tibia and fibula of 2 mm or more has been considered pathologic.9 Earlier biomechanical study demonstrated the Fibulink system is superior in maintaining displacement of less than 2 mm.4 Given the improved strength, we also look to evaluate the outcomes of initiating full weight bearing (100%) with Controlled Ankle Motion (CAM) boot at 4 weeks postoperatively. One of the big limitations for trans-osseous screw fixation is delayed weight bearing due to risk of screw breakage.1 Suture button technique allowed for early weight bearing with average of 6 weeks postoperatively using TightRope.2,10-12By initiating full weight bearing (100%) with CAM boot at 4 weeks postoperatively, this would be a significant improvement in current clinical practice.
Being studied: Early Weight Bearing; Normal Weight Bearing
Conditions: Ankle Fractures; Bimalleolar Fractures; Syndesmotic Injuries; Bimalleolar Equivalent Fracture; Maisonneuve Fracture; Trimalleolar Fractures; Ankle Dislocation
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- ankle fracture with syndesmotic disruption as assessed with intra-operative cotton test.
This includes the following injuries
- Syndesmotic sprain (without fractures)
- Bimalleolar equivalent ankle fractures
- Bimalleolar ankle fractures
- Maisonneuve fractures
- Trimalleolar ankle fractures without the need for posterior malleolus fixation
- Ankle fracture dislocations
Exclusion Criteria
- 1) previous ankle surgery, 2) active local infection about the ankle, 3) chronic ankle deformity secondary to trauma or congenital, 4) ligamentous laxity, 5) pathologic fractures, 6) peripheral vascular disease, 7) peripheral neuropathy, 8) diabetes neuropathy and charcot, 9) open fractures, 10) poly trauma, 11) inability to provide informed consent, 12) symptomatic ankle osteoarthritis, 12) retained hardware, 13) pregnant, 14) metabolic bone disease, 15) history of chronic steroid use, 16) mal-reduced ankle fractures
Recruiting US locations
Maimonides Medical Center
Brooklyn, NY 11219
Site contact: Antonios Likourezos · 718-283-6896 · alikourezos@maimonidesmed.org
Study contacts (from the official record)
- Amr A Abdelgawad, MD PhD MBA · 7182837400 · aabdelgawad@maimonidesmed.org
- Ariel N Rodriguez, MD · 7182837400 · arrodriguez@maimonidesmed.org
Similar studies in New York
All healthy volunteers studies in New York →- RecruitingHealthy volunteers
Using Middle School Science Teachers to Address Cancer Health Disparities
Weill Medical College of Cornell University
- Location
- New York, NY + 1 other US site
- Eligibility basics
- Ages 10+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- New York, NY + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Staten Island, NY + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- East Syracuse, NY + 14 other US sites
- Eligibility basics
- Ages 2 mo–1